Brooks Laboratories
Brooks Laboratories Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Brooks Laboratories Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Brooks Laboratories Ltd trades at a P/E of 10.00× and P/B of 1.87×.
Valuation
Profitability
Growth
Financial Health
Brooks Laboratories Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Brooks Laboratories Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Brooks Laboratories Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Brooks Laboratories Ltd, switchable between annual and quarterly views, consolidated or standalone.
Brooks Laboratories Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹200.6 Cr and reported EPS of ₹7.32.
| Period | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue from Operations | 77 | 91 | 63 | 79 | 83 | 86 |
| Other Income | 1 | 1 | 0 | 1 | 1 | 1 |
| Total Income | 78 | 92 | 63 | 80 | 83 | 87 |
| Cost of Goods Sold (COGS) | 48 | 63 | 51 | 57 | 54 | 51 |
| Gross Profit | 30 | 28 | 13 | 23 | 28 | 35 |
| +Operating Expenses | 29 | 43 | 39 | 20 | 24 | 28 |
| EBITDA | 1 | -14 | -26 | 3 | 5 | 7 |
| +Non-Operating Expenses | 10 | 10 | 9 | 3 | 3 | 2 |
| Profit Before Tax (PBT) | -9 | -24 | -36 | 2 | 3 | 6 |
| +Tax Expense | 10 | -5 | -7 | 0 | 0 | — |
| Profit After Tax (PAT) | -19 | -19 | -32 | -20 | -10 | 25 |
| Earnings Per Share (EPS) | -7.38 | -6.17 | -7.96 | -7.46 | -3.38 | 8.34 |
| Diluted Shares Outstanding (Nos.) | 3 | 3 | 3 | 3 | 3 | 3 |
| +Additional Disclosures | 135 | 176 | 136 | 114 | 121 | 151 |
| Sales Growth % | — | 17.90 | -30.60 | 25.76 | 3.86 | 3.85 |
| YoY Sales Growth % | — | 17.90 | -30.60 | 25.76 | 3.86 | 3.85 |
| Material Cost % | 60 | 69 | 66 | 56 | 57 | 58 |
| Employee Cost % | 19 | 21 | 27 | 13 | 16 | 18 |
| Other Cost % | 19 | 26 | 34 | 11 | 13 | 15 |
| OPM % | 1 | -16 | -42 | 4 | 6 | 8 |
| Tax % | -116 | 19 | 20 | 2 | 5 | — |
| Profit Growth % | — | 0.32 | -64.49 | 38.33 | 49.13 | 346.65 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | -7 | -22 | -33 | 1 | 3 | 5 |
Brooks Laboratories segment analysis: revenue and profit mix.
Disclosed business segments at Brooks Laboratories with their share of revenue and profit, switchable between consolidated and standalone reporting.
Brooks Laboratories discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Brooks Laboratories Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Brooks Laboratories Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Brooks Laboratories Ltd's investment case rests on 7 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Brooks Laboratories has demonstrated a remarkable turnaround in its latest quarter, reporting a substantial 498.00% increase in net profit, reaching 9.58 Cr. This strong quarterly performance indicates improving operational efficiency and a positive shift in profitability.
The company has shown robust top-line growth, with quarterly sales increasing by an impressive 42.30% to 25.5 Cr. This significant sales expansion suggests growing market demand and effective business strategies.
Brooks Laboratories maintains a very healthy financial structure with a low debt-to-equity ratio of 0.08. This indicates minimal reliance on borrowed capital, providing financial stability and flexibility for future growth initiatives.
Promoter holding remains substantial at 52.62% as of 2025-09-01, reflecting strong confidence from the core management in the company's long-term prospects and strategic direction, aligning interests with shareholders.
Operating within the 'Pharmaceuticals' sector, Brooks Laboratories can capitalize on the robust and expanding global healthcare market. Increasing demand for medicines and healthcare services presents significant growth avenues for the company.
What can break it.
The company's stock trades at a very high P/E ratio of 153.00, significantly above industry averages. This valuation suggests the stock might be overvalued, posing a risk for potential investors seeking reasonable entry points.
Brooks Laboratories exhibits negative returns on capital employed (-9.93%), equity (-12.20%), and assets (-9.33%). This indicates the company is not effectively generating profits from its capital and assets, a major concern.
The operating profit margin (OPM) stands at a negative -3.37%, indicating that the company's core operations are not generating sufficient profit to cover operating costs. This highlights a need for improved cost management.
The stock has experienced significant price volatility, dropping from a 52-week high of 203.00 to its current 106.00. Recent 5-day data also shows a decline, indicating potential investor apprehension and downward pressure.
The company currently offers a 0.00% dividend yield, meaning it does not distribute profits to shareholders. This might deter income-focused investors and suggests a focus on reinvestment or insufficient profitability for payouts.
What would change my mind.
Trim if P/E re-rates above 13. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Brooks Laboratories Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Brooks Laboratories Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Brooks Laboratories Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Brooks Laboratories Ltd — derived from the live tape, not yesterday's close.
Brooks Laboratories Ltd last traded at ₹69.58 with an intraday range of ₹69.01–₹71.89 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹69.58| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 77.07 | +7.49 | +10.76% |
| R3 | 74.19 | +4.61 | +6.63% |
| R2 | 73.04 | +3.46 | +4.97% |
| R1 | 71.31 | +1.73 | +2.49% |
| PIVOT | 70.16 | 0.58 | 0.83% |
| CURRENT | 69.58 | — | — |
| S1 | 62.67 | -6.91 | -9.93% |
| S2 | 65.55 | -4.03 | -5.79% |
| S3 | 67.28 | -2.30 | -3.31% |
| S4 | 68.43 | -1.15 | -1.65% |
BROOKS is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ~
Trading Below opening range, showing Bearishness
Brooks Laboratories Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Brooks Laboratories Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Brooks Laboratories Ltd stood at 59.7% of traded volume, against a 20-day average of 51.3%.
Brooks Laboratories announcements: results, concalls, ratings, M&A.
Filings Brooks Laboratories sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Brooks Laboratories files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 34 documents below.
Copy of Newspaper Publication
Newspaper Publication dated 30th May 2026 of Audited Financial Results for the quarter and year ended 31st March 2026.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st March 2026.
Disclosure under SEBI Takeover Regulations
Atul Ranchal has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial…
Price movement
Significant movement in price has been observed in Brooks Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant…
Price movement
Significant movement in price has been observed in Brooks Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant…
Investor decks & rating reports.
Brooks Laboratories dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Brooks Laboratories has declared, sequenced by announce and record date.
Brooks Laboratories corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Brooks Laboratories Ltd: business, sector, key facts.
What Brooks Laboratories Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Brooks Laboratories Ltd operates in the Life Sciences Tools & Services industry under the Health Care sector, listed as NSE: BROOKS, BSE: 533543.
Brooks Laboratories Limited is a pharmaceutical company headquartered in Mumbai, India, that was established in 2002. Its primary business revolves around the manufacturing and sale of a diverse range of pharmaceutical products both domestically within India and in international markets.
The company's product portfolio encompasses a broad spectrum of dosage forms designed to cater to various medical needs. This includes liquid and dry powder injections, a specialized area focusing on carbapenem dry powder injectables, which are likely used to treat serious bacterial infections. They also produce tablets, oral suspensions (liquids taken orally), dry syrups (syrups in powder form requiring reconstitution), and ophthalmic and otic preparations (eye and ear drops respectively).
The wide variety of dosage forms suggests Brooks Laboratories caters to a broad range of therapeutic areas. While the specific therapeutic categories aren't explicitly stated, the inclusion of carbapenem injectables indicates a focus on treating severe bacterial infections, while the presence of oral and topical formulations (tablets, syrups, eye/ear drops) demonstrates a broader commitment to various treatment needs.
Brooks Laboratories' business model centers on the production and distribution of its pharmaceutical products. The company's international presence suggests a commitment to exporting its products, indicating a strategy focused on both the domestic Indian market and global markets. The success of this business likely depends on factors such as manufacturing efficiency, regulatory compliance in multiple markets, effective distribution networks, and the ongoing development of new and improved pharmaceutical formulations.
In summary, Brooks Laboratories Limited is a significant player in the Indian pharmaceutical industry, actively engaged in manufacturing and distributing a diverse range of pharmaceutical products across multiple dosage forms and likely therapeutic areas. Their international reach and focus on injectable medications, particularly carbapenems, indicate a dedication to addressing significant medical needs both within India and globally.
Questions investors ask about Brooks Laboratories Ltd (BROOKS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Brooks Laboratories Ltd (BROOKS)?
The current share price of Brooks Laboratories Ltd (BROOKS) is ₹69.58. Today, the stock has declined by ₹2.49 (3.45%), trading in a range of ₹69.01 to ₹71.89. The stock opened at ₹71.79 with a trading volume of 91,999 shares.
02Is Brooks Laboratories Ltd stock a good investment for long-term?
Brooks Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹200.6 crores, P/E ratio of 10.00, ROE of 6.10%, and ROCE of -9.93%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Brooks Laboratories Ltd stock?
The 52-week high price of Brooks Laboratories Ltd (BROOKS) is ₹164.02, while the 52-week low is ₹36.3. Currently trading at ₹69.58, the stock is 26.1% away from its 52-week low and 57.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Brooks Laboratories Ltd stock at the current price?
Whether to buy Brooks Laboratories Ltd stock at ₹69.58 depends on multiple factors. The stock is currently trading with a P/E ratio of 10.00 and P/B ratio of 1.87. Today's performance shows a loss of 3.45%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Brooks Laboratories Ltd and when is the next dividend?
Brooks Laboratories Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹69.58, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Brooks Laboratories Ltd?
Brooks Laboratories Ltd's key financial metrics include: P/E Ratio: 10.00, P/B Ratio: 1.87, ROE: 6.10%, ROCE: -9.93%, Dividend Yield: 0.00%, EPS: ₹7.32, Book Value: ₹33.3, and Debt-to-Equity: 0.08. The company's market cap stands at ₹200.6 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Brooks Laboratories Ltd stock performing today in the market?
Brooks Laboratories Ltd stock opened at ₹71.79 and is currently trading at ₹69.58, showing a decline of ₹2.49 (3.45%). The intraday high is ₹71.89 and low is ₹69.01. The trading volume stands at 91,999 shares, indicating moderate market participation today.
08What is the P/E ratio of Brooks Laboratories Ltd and what does it indicate?
Brooks Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 10.00, which means investors are willing to pay ₹10.00 for every ₹1 of earnings. With an EPS of ₹7.32, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Brooks Laboratories Ltd (BROOKS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy